When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not enough to just conquer Australia. If you want to use the continent as a launch pad to take over the world, you need to design and execute on a long-term strategy.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC
The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis – the promise of these advantages has made targeted protein degradation one of the most exciting new therapeutic modalities of the past 30 years.
By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC.
In a landmark study, researchers successfully used CRISPR to directly edit DNA in humans, a milestone that could pave the way for treatments for scores of serious genetic and non-genetic diseases.
I was in the passenger seat, trying desperately not to reach for the grab handle, saying reassuring things but thinking ‘those mailboxes are really close’.
By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC
Spring in New England is in full bloom. All around birds are chirping, flowers are blooming, and there is sweetness (and pollen) everywhere. Life is anew. Really anew. I don’t know about you, but this spring feels particularly poignant. The pandemic isolation was long, personal, and collectively traumatic. Having the seasonal change of nature’s new life coincide with vaccinations climbing and COVID cases decreasing, has me almost sprinting back to the office.
By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.